PDT Partners’s Cardiff Oncology CRDF Stock Holding History

PDT Partners’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-504	Closed	-$369K	–	1319
2015 Q2	$369K	Buy	+504	New	+$357K	0.01%	1070

Other funds holding CRDF

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MWVC

Morgens Waterfall Vintiadis & Co New York $81.2M AUM 86.87% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PDT Partners's CRDF Position: Q3 2015 in Review

PDT Partners sold out of Cardiff Oncology (CRDF) in Q3 2015, closing a stake of 504 shares — an estimated $369K sold.

PDT Partners first reported a position in CRDF in Q2 2015 and held it in 1 quarter. The position peaked at $369K in Q2 2015. 60 funds tracked by Wall St. Rank hold CRDF as of Q3 2015.

PDT Partners reported no remaining Cardiff Oncology position as of Q3 2015 after selling out during the quarter.
PDT Partners sold 504 Cardiff Oncology shares in Q3 2015, an estimated $369K.
PDT Partners first reported a position in Cardiff Oncology in Q2 2015 and held it in 1 quarter.
PDT Partners's Cardiff Oncology position peaked at $369K in Q2 2015.
60 funds tracked by Wall St. Rank held Cardiff Oncology as of Q3 2015.

Based on PDT Partners's 13F filing for Q3 2015, filed 16 Nov 2015.